Medpace (NASDAQ:MEDP) General Counsel Stephen Ewald Sells 16,349 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) General Counsel Stephen Ewald sold 16,349 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Medpace Trading Up 1.0%

MEDP opened at $451.47 on Tuesday. The stock has a market cap of $12.89 billion, a PE ratio of 28.38, a P/E/G ratio of 2.27 and a beta of 1.19. Medpace Holdings, Inc. has a 1 year low of $291.28 and a 1 year high of $628.92. The stock’s 50 day simple moving average is $457.28 and its 200-day simple moving average is $512.30.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Levi & Korsinsky, the Schall Law Firm, DJS Law Group, and others, reminded investors that a class action has been filed against Medpace and certain officers, keeping legal overhang and potential liability in focus. Article: MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit
• Negative Sentiment: The lawsuit reminders may reinforce concerns that Medpace could face damages, legal costs, or reputational pressure if the allegations gain traction. Article: MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit
• Neutral Sentiment: One disclosed insider transaction showed Medpace General Counsel Stephen P. Ewald sold 16,349 shares at $450 each, a move that may draw investor attention but does not by itself establish a broader business trend. Article: SEC Form 4 filing for Stephen P. Ewald

Analyst Ratings Changes

A number of analysts have recently issued reports on MEDP shares. Truist Financial lowered their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Royal Bank Of Canada decreased their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. BMO Capital Markets decreased their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, TD Cowen raised Medpace from a “sell” rating to a “hold” rating and decreased their price target for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $467.08.

Institutional Trading of Medpace

Several large investors have recently made changes to their positions in MEDP. NewEdge Advisors LLC grew its holdings in shares of Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Medpace during the second quarter worth $296,000. Finally, M&T Bank Corp grew its holdings in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.